bluebird bio (BLUE) Upgraded to “Hold” at BidaskClub

bluebird bio (NASDAQ:BLUE) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday, May 7th, BidAskClub reports.

Other research analysts also recently issued reports about the stock. SunTrust Banks decreased their target price on shares of bluebird bio to $184.00 and set a “buy” rating on the stock in a research note on Monday, February 25th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of bluebird bio in a research report on Thursday, January 10th. Canaccord Genuity reaffirmed a “buy” rating and set a $161.00 price target (down previously from $250.00) on shares of bluebird bio in a research report on Wednesday, January 23rd. ValuEngine upgraded bluebird bio from a “hold” rating to a “buy” rating in a research note on Friday, March 1st. Finally, Zacks Investment Research upgraded bluebird bio from a “hold” rating to a “buy” rating and set a $160.00 price target on the stock in a report on Monday, April 29th. Eleven research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $168.29.

Shares of BLUE stock traded down $1.72 during trading hours on Tuesday, hitting $120.53. 255,000 shares of the company’s stock were exchanged, compared to its average volume of 515,494. The company has a market capitalization of $6.81 billion, a PE ratio of -11.29 and a beta of 2.50. bluebird bio has a 12-month low of $87.49 and a 12-month high of $199.70. The company has a debt-to-equity ratio of 0.09, a quick ratio of 9.31 and a current ratio of 9.31.

bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($2.99) EPS for the quarter, missing the consensus estimate of ($2.79) by ($0.20). The business had revenue of $12.47 million for the quarter, compared to analysts’ expectations of $15.49 million. bluebird bio had a negative return on equity of 34.01% and a negative net margin of 1,184.01%. The company’s revenue was down 21.9% compared to the same quarter last year. During the same period last year, the business posted ($2.31) earnings per share. On average, research analysts predict that bluebird bio will post -12.2 EPS for the current year.

In related news, insider Jeffrey T. Walsh sold 1,500 shares of the firm’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $139.80, for a total transaction of $209,700.00. Following the sale, the insider now owns 42,421 shares of the company’s stock, valued at $5,930,455.80. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider David Davidson sold 3,101 shares of the firm’s stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $146.41, for a total value of $454,017.41. Following the sale, the insider now directly owns 34,717 shares in the company, valued at approximately $5,082,915.97. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 25,231 shares of company stock worth $3,763,677. 3.00% of the stock is owned by corporate insiders.

Several large investors have recently made changes to their positions in the company. Marshall Wace LLP purchased a new stake in shares of bluebird bio in the first quarter valued at approximately $6,117,000. Clearbridge Investments LLC boosted its stake in shares of bluebird bio by 18.2% in the first quarter. Clearbridge Investments LLC now owns 839 shares of the biotechnology company’s stock worth $132,000 after acquiring an additional 129 shares during the last quarter. B. Riley Wealth Management Inc. acquired a new stake in shares of bluebird bio in the first quarter worth approximately $315,000. Gilder Gagnon Howe & Co. LLC boosted its stake in shares of bluebird bio by 152.1% in the first quarter. Gilder Gagnon Howe & Co. LLC now owns 38,929 shares of the biotechnology company’s stock worth $6,125,000 after acquiring an additional 23,486 shares during the last quarter. Finally, FMR LLC boosted its stake in shares of bluebird bio by 0.5% in the first quarter. FMR LLC now owns 8,242,676 shares of the biotechnology company’s stock worth $1,296,820,000 after acquiring an additional 38,515 shares during the last quarter.

bluebird bio Company Profile

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder.

Further Reading: How to Profit and Limit Losses With Stop Orders

Analyst Recommendations for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.